London-based menstrual health company DITTO has secured $6 million in seed funding to expand its supplement range and clinical research programme.

FoodLabs led the investment round, with existing investor Eka Ventures returning after leading a £1.35 million pre-seed raise in August 2025. The funding puts the transaction in the top 6% of all UK health seed deals. Since launching in 2024, the business has grown its team from two co-founders to 15 employees, adding a specialist GP and a gynaecologist as medical advisors.

Co-founded by neuroscientist and nutrition scientist Alice van der Schoot alongside former L’Oréal Brand Director Adam Kugler, the company combines targeted formulations with scientific research. Its flagship product, Premenstrual Daily, utilises a beadlet-in-oil delivery technology that layers 10 ingredients to release them in stages. This system reduces competition between nutrients in the gut to improve absorption. In a recent clinical trial, 88% of participants reported reduced symptom severity.

DITTO plans to run three further clinical trials and publish five research papers over the next 12 months. The research agenda includes a study investigating links between premenstrual dysphoric disorder (PMDD) and ADHD. The firm relies on a community of over 300,000 members to inform its product development and research goals.

The global market for women’s hormonal supplements is projected to reach $7.5 billion by 2030. However, the company argues that generic products are falling short of consumer expectations, pointing to UK guidance that recommends warm baths or stomach massages despite 90% of women experiencing premenstrual symptoms.

“Women’s health has many distinct and complex subsections — different conditions, different symptoms, different underlying biology and different life stages — each deserving targeted, expert-level supplements,” she told Nutraceutical Business Review.

The next generation of successful supplement brands will be those that combine both: specificity and product-level clinical evidence.

“Women are increasingly sceptical that supplements over-promise and under-deliver,” she explained.

It’s the combination of an evidence-based formulation and nutrient delivery biotechnology that makes the supplement highly effective.

“In the market of menstrual health, clinical evidence is becoming the price of entry, and the first company to set that standard is the one everyone else gets measured against,” says Flo Breiner, an operating partner at FoodLabs.

Camilla Dolan, general partner at Eka Ventures, calls the thesis straightforward: “The science earns trust, and trust is what scales a brand.”